Aesther Healthcare Acquisition Corp. (AEHAU)
Chart Events
Performance Outlook
| Previous Close | 10.55 |
| Open | 10.55 |
| Bid | 9.49 x 800 |
| Ask | 11.62 x 2200 |
| Day's Range | 10.55 - 10.55 |
| 52 Week Range | 10.12 - 10.61 |
| Volume | |
| Avg. Volume | 49 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types Ocean Biomedical is expected to become a publicly traded company on the NASDAQ global market under the symbols “OCEA” and “OCEAW” following the closing of a Business Combination with Aesther Corporation Providence, RI and New York, NY, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare A
- GlobeNewswire
Ocean Biomedical Provides Corporate Update and Company Summary
Ocean Biomedical stock is expected to trade on the Nasdaq Capital Market under ticker symbol "OCEA" PROVIDENCE, RI and NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities. Built on Ocean Biomedical’s expertise in technology transfer, a unique business model was created to br
- GlobeNewswire
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transactio
